An Approved Drug to Study a New Indication for Allergic Rhinitis

See also
Status	Clinical Trial	Phase
Terminated	`NCT01337323` - Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting	N/A
Completed	`NCT00851344` - Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo	Phase 2
Completed	`NCT00501527` - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense	Phase 2
Completed	`NCT00537355` - An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber	Phase 2
Completed	`NCT00422149` - Twin SUBLIVAC® Grasses Clinical Efficacy Study	Phase 3
Completed	`NCT00542607` - Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis	Phase 4
Completed	`NCT00605852` - Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects	Phase 1
Active, not recruiting	`NCT05960266` - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study	Early Phase 1
Completed	`NCT02256553` - Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)	Phase 4
Completed	`NCT00932256` - Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients	Phase 1
Completed	`NCT01007721` - Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season	Phase 2
Completed	`NCT00901914` - Study of rBet v1 Tablets	Phase 2
Completed	`NCT00384475` - A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)	Phase 3
Completed	`NCT00839189` - Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults	Phase 1
Completed	`NCT00135629` - Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever	Phase 3
Completed	`NCT04687059` - An Exploratory Study of PQ Grass 27600 SU	Phase 2/Phase 3
Completed	`NCT00889460` - Safety and Tolerability Study of rBet v1 SLIT Tablets	Phase 1
Completed	`NCT00396149` - Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1	Phase 1
Completed	`NCT00659594` - Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)	Phase 3
Completed	`NCT01480271` - An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.	Phase 1

NCT number	NCT00127647
Study type	Interventional
Source	Organon and Co
Contact
Status	Completed
Phase	Phase 3
Start date	November 2004
Completion date	April 2005

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms